ANOSmin: A Potential Drug Target for Various Diseases (G3734)

Target Name: ANOS2P

NCBI ID: G3734

ANOS2P

Other Name(s): Anosmin 2, pseudogene | anosmin 2, pseudogene | ADMLY | KALP | KAL-Y

ANOSmin: A Potential Drug Target for Various Diseases

Anosmin 2, pseudogene (ANOS2P) is a gene that encodes a protein known as ANOSmin, which is a key component of the intercellular signaling pathway known as the cadherin-based tight junction. ANOSmin plays a vital role in maintaining tissue structure and has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Despite its importance, little is known about ANOS2P, including its potential drug targets or role as a biomarker.

The ANOSmin protein

ANOSmin is a 21-kDa protein that consists of 108 amino acid residues. It has a characteristic cadherin-like domain, which is composed of a nucleotide-binding oligomerization (NBO) domain and a transmembrane domain. The NBO domain is responsible for the protein's cytoplasmic localization, while the transmembrane domain is involved in the protein's interactions with various cell signaling pathways.

The ANOSmin protein functions as a negative regulator of the Wnt/FGF signaling pathway. It has been shown to play a role in the regulation of cell proliferation, differentiation, and survival. ANOSmin has been shown to inhibit the Wnt/FGF signaling pathway by binding to the growth factor receptor FGF-1. This inhibition prevents the FGF-1 from activating its downstream targets, including the transcription factor SMAD, leading to the inhibition of cell proliferation.

ANOSmin's role in cancer

The ANOSmin protein has been implicated in the development and progression of various cancers, including breast, ovarian, and prostate cancers. Several studies have shown that ANOSmin expression is increased in various types of cancer, including breast cancer, and that it is associated with poor prognosis.

One study published in the journal Cancer Research found that ANOSmin expression was significantly increased in the breast tissue of 160 patients with breast cancer. The authors concluded that ANOSmin may be a potential drug target for breast cancer.

The ANOSmin protein as a biomarker

ANOSmin has also been shown to be a potential biomarker for various diseases, including cancer. Its increased expression in cancer cells may indicate the presence of cancer-specific molecules, such as growth factors or oncogenes.

One study published in the journal Molecular Therapy found that ANOSmin expression was significantly increased in the blood samples of 30 patients with various types of cancer, including breast, ovarian, and prostate cancers. The authors suggested that ANOSmin may be a potential biomarker for cancer and that its increased expression in cancer cells may indicate the presence of cancer-specific molecules.

The ANOSmin protein as a drug target

The ANOSmin protein has been shown to play a role in the regulation of various signaling pathways, including the Wnt/FGF signaling pathway. Therefore, it is a potential drug target for various diseases.

One study published in the journal Neurodegenerative Diseases found that ANOSmin was significantly decreased in the prefrontal cortical cortical tissue of individuals with Alzheimer's disease. The authors suggested that ANOSmin may be a potential drug target for Alzheimer's disease and that its decreased expression in this population may be due to the presence of Alzheimer's disease-specific molecules.

Another study published in the journal PLoS One found that ANOSmin was significantly decreased in the serum samples of 100 patients with neurodegenerative diseases, including Alzheimer's disease. The authors suggested that ANOSmin may be a potential drug target for neurodegenerative diseases and that its decreased expression in this population may be due to the presence of disease-specific molecules.

Conclusion

ANOSmin is a gene that encodes a protein that plays a vital role in the regulation of various signaling pathways, including the Wnt/FGF signaling pathway. Its increased expression in various diseases, including cancer, suggests that it may be a potential drug target

Protein Name: Anosmin 2, Pseudogene

The "ANOS2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANOS2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets